Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

“The rapid evolution of the pharmaceutical industry ... To ensure market exclusivity, Novo Nordisk and Eli Lilly have secured patents for these drugs worldwide. In Brazil, the primary patent ...

In the kitchen of her South St. Paul home, Abigail Turner prepares the insulin she uses to manage her type 1 diabetes last February. Minnesota announced a final settlement Monday with the last of ...

can buy Novo Nordisk’s insulin products for $35 per month for the next five years. The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its ...

Novo Nordisk A/S on Monday became the final insulin manufacturer to reach a proposed settlement agreement with Minnesota, tentatively ending a seven-year lawsuit over the affordability of the diabetes ...

Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products by agreeing to cap costs at $35 per month. Under the settlement ...